Related references
Note: Only part of the references are listed.Towards Non Invasive Nerve Growth Factor Therapies for Alzheimer's Disease
Antonino Cattaneo et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent Cerebrolysin
X. Anton Alvarez et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2009)
Depression, comorbidities and the TNF-α system
H. Himmerich et al.
EUROPEAN PSYCHIATRY (2008)
Amyloid-beta immunisation for Alzheimer's disease
Thomas Wisniewski et al.
LANCET NEUROLOGY (2008)
Pharmacotherapy of Alzheimer disease
Dennis Seow et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2007)
Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis
Honghui Chen et al.
NEUROBIOLOGY OF AGING (2007)
Treatment of moderate to severe Alzheimer's disease: Rationale and trial design
Nathan Herrmann
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2007)
Effects of Cerebrolysin™ on neurogenesis in an APP transgenic model of Alzheimer's disease
Edward Rockenstein et al.
ACTA NEUROPATHOLOGICA (2007)
Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy
Sinead M. O'Brien et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2007)
Cerebrolysin decreases amyloid-β production by regulating amyloid protein precursor maturation in a Transgenic model of Alzheimer's disease
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
XA Alvarez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
R Bullock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Disease stage in Alzheimer disease and treatment effects of rivastigmine
A Kurz et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2004)
Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease
D Galasko et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2004)
Long-term effects of rivastigmine in moderately severe Alzheimer's disease - Does early initiation of therapy offer sustained benefits?
PM Doraiswamy et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2002)
Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease
S Gauthier et al.
CURRENT MEDICAL RESEARCH AND OPINION (2002)
Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent
M Panisset et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease
E Ruether et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2001)
A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer's disease
CY Bae et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2000)